Repligen Gestione
Criteri Gestione verificati 4/4
Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.
Informazioni chiave
Olivier Loeillot
Amministratore delegato
US$6.1m
Compenso totale
| Percentuale dello stipendio del CEO | 14.06% |
| Mandato del CEO | 2.7yrs |
| Proprietà del CEO | n/a |
| Durata media del management | 2.5yrs |
| Durata media del Consiglio di amministrazione | 10.3yrs |
Aggiornamenti recenti sulla gestione
Recent updates
Aggiornamento della narrazione • Jun 13
RGEN: Bioprocess Recovery And Training Hub Expansion Will Guide Future Performance
Repligen's analyst price target has been reset slightly lower to $142, as analysts factor in a modestly higher discount rate along with still-supportive views on bioprocessing demand and the broader life science tools recovery. Analyst Commentary Recent Street research around Repligen reflects a mixed setup, with several firms trimming price targets and a few others highlighting potential recovery in bioprocessing demand.Seeking Alpha • May 31
Repligen Has A Cleaner Recovery Angle, But With High Valuation
Summary Repligen is recovering after a difficult 2024, with Q1 2026 revenue up 15% and 11% organic. Polymem, China, PAT, and the Transformation Office make the story cleaner, but execution still matters. I like Repligen's balance sheet, as it has plenty of liquidity with good cash flows to continue funding M&A deals or potential growth in Asia. Unfortunately, my main issue with RGEN is its expensive valuation, which leaves little margin of safety for investors at these levels. Read the full article on Seeking AlphaAggiornamento della narrazione • May 30
RGEN: Firmer Bioprocess Backdrop And Hubs Expansion Will Shape Long Term Outlook
Repligen's updated analyst price target of $142 reflects a largely unchanged fair value. Analysts point to a mix of reduced P/E assumptions and slightly stronger expectations for revenue growth and profitability, supported by recent research that highlights a firmer bioprocess backdrop and diversified growth drivers.Aggiornamento della narrazione • May 11
RGEN: Recalibrated Street Expectations And Hubs Expansion Will Shape Long Term Outlook
Analysts now place Repligen's fair value at $142, a $2 adjustment that reflects a mix of recent price target cuts and increases as they weigh updated growth expectations, margins, and P/E assumptions from the latest round of Street research. Analyst Commentary The latest Street research on Repligen shows a split tape, with some firms lifting targets and others cutting them, which nets out to the modest US$2 bump in the aggregated fair value estimate to US$142.Aggiornamento della narrazione • Apr 25
RGEN: recalibrated Street Expectations Will Shape Bullish Long Term Outlook
The analyst price target for Repligen has been reduced from about $160.90 to $140.00, as analysts factor in updated assumptions for revenue growth, profit margins, discount rates and future P/E following a mix of recent target cuts and one upward revision across the Street. Analyst Commentary Street research on Repligen over recent months points to a mixed but generally more cautious stance, with several firms trimming price targets while one research house lifted its target.
Aggiornamento della narrazione • Apr 09
RGEN: Multi Year Guidance And M&A Dry Powder Will Support Future Upside
Narrative Update on Repligen The analyst price target for Repligen has been adjusted slightly lower, with the updated fair value moving from about $186.82 to $183.88 as analysts factor in recent target cuts, alongside generally positive views on guidance and execution. Analyst Commentary Recent Street research on Repligen clusters around a group of target cuts following the latest Q4 report and FY26 outlook, alongside a smaller number of target increases.Aggiornamento della narrazione • Mar 25
RGEN: Multi Year Guidance And M&A Focus Will Support Future Upside
Repligen's analyst price target has been adjusted modestly higher to $186.82, with analysts pointing to refreshed assumptions around revenue growth, profit margins, and future P/E expectations following recent target changes across firms such as H.C. Wainwright, UBS, Evercore ISI, Wells Fargo, and Barclays. Analyst Commentary Recent target changes reflect a mix of optimism and caution around Repligen, with analysts adjusting their models after the latest Q4 results and FY26 guidance.Aggiornamento della narrazione • Mar 10
RGEN: M&A And New Bioprocessing Resins Will Support Future Upside
Narrative Update: Repligen Repligen's updated analyst price target reflects a modest reset, with fair value moving from about $190.89 to $186.28 as analysts factor in slightly lower revenue growth and profit margin assumptions along with a marginally higher discount rate, while still generally highlighting solid recent execution and cautious company guidance. Analyst Commentary Recent Street research on Repligen shows a mixed but generally constructive stance, with several firms trimming price targets while maintaining positive ratings.Aggiornamento della narrazione • Feb 24
RGEN: M&A Focus And New Bioprocessing Resins Will Drive Future Upside
Analysts have raised their Repligen price target by $10 to $190.89, citing updated assumptions for discount rates, revenue growth, profit margins, and future P/E as reflected in recent Street research. Analyst Commentary Bullish Takeaways Bullish analysts see the higher US$190.89 price target as better aligned with updated assumptions for discount rates and future P/E, suggesting the shares may not fully reflect their revised valuation framework.Aggiornamento della narrazione • Feb 09
RGEN: M&A Ambitions And New Resins Portfolio Will Shape Bullish Outlook
Analysts have lifted their price target on Repligen by US$10, citing updated assumptions that reflect revised fair value estimates, a tweaked discount rate, adjusted revenue growth and profit margin expectations, and an updated future P/E multiple. Analyst Commentary Even with the higher price target, some research commentary points to risks that readers should keep in mind when weighing Repligen at current levels.Aggiornamento della narrazione • Jan 26
RGEN: Process Analytics Strength And Biopharma Recovery Will Support Further Upside
Analysts have nudged their price targets on Repligen higher, with our updated fair value estimate moving modestly to about US$190.89 per share. This is supported by recent Street research citing raised targets following a 3Q25 revenue beat and a relatively improving biopharma outlook, with growth across all franchises led by Process Analytics.Aggiornamento della narrazione • Jan 12
RGEN: Process Analytics Strength And Biopharma Recovery Will Support Upside In 2025
Analysts have lifted their price target on Repligen to about US$190 from US$187, pointing to recent target raises, including Canaccord's move to US$165 on 3Q25 revenue outperformance, a relatively improving biopharma outlook, and solid contributions from Process Analytics and other franchises. Analyst Commentary Bullish Takeaways Bullish analysts see the move to a higher price target as a reflection of stronger than expected 3Q25 revenue, which they view as supportive of the current valuation range.Aggiornamento della narrazione • Dec 27
RGEN: Process Analytics Momentum And Biopharma Recovery Will Shape Risk Balanced Outlook
Narrative Update We are raising our Repligen fair value estimate from $131.29 to $160.36 per share as analysts lift price targets toward $160 to $165 on better than expected Q3 results, broad-based revenue growth led by Process Analytics, and an improving outlook for biopharma end markets. Analyst Commentary Recent Street research reflects a cautiously constructive stance on Repligen, with higher price targets acknowledging near term execution outperformance while still embedding meaningful risk around sustainability of growth.
Aggiornamento della narrazione • Dec 13
RGEN: Bioprocessing Recovery And Guidance Raise Will Support Upside Potential
Analysts have nudged our Repligen price target higher to $165, reflecting a modest trim to fair value estimates to about $216.62 per share, alongside slightly lower long term revenue growth and discount rate assumptions, but reinforced by recent target increases from the Street on better than expected quarterly results, improving biopharma demand, and confidence in the company s bioprocessing driven double digit growth potential. Analyst Commentary Bullish analysts have become incrementally more constructive on Repligen following its recent quarterly performance, citing a healthier biopharma demand backdrop and stronger than expected execution across key franchises.Aggiornamento della narrazione • Nov 27
RGEN: Volume Recovery and End-Market Stability Will Support Measured Upside in 2025
Narrative Update on Repligen Analysts have raised their price targets on Repligen by up to $15. They cite stronger-than-expected quarterly results and improved industry outlooks as driving positive momentum for the company.Articolo di analisi • Nov 12
Repligen's (NASDAQ:RGEN) Earnings May Just Be The Starting Point
Even though Repligen Corporation ( NASDAQ:RGEN ) posted strong earnings, investors appeared to be underwhelmed. We did...Aggiornamento della narrazione • Nov 11
RGEN: End-Market Improvements Will Drive Stronger Momentum Through 2025
Analysts have increased their price target for Repligen slightly, from $184.76 to $187.00. They cite a recent revenue beat, an improving sector outlook, and expectations for continued growth across key business areas.Articolo di analisi • Oct 31
Repligen Corporation Just Beat EPS By 18%: Here's What Analysts Think Will Happen Next
Repligen Corporation ( NASDAQ:RGEN ) investors will be delighted, with the company turning in some strong numbers with...Aggiornamento della narrazione • Oct 28
Recovery In Industry Demand And Market Stability Will Drive Renewed Momentum
Repligen's analyst price target has been increased from $179.78 to $184.76, as analysts see improving market stability and anticipate a return to stronger revenue growth despite recent headwinds. Analyst Commentary Recent updates from street research highlight a renewed sense of optimism among analysts, along with acknowledgment of ongoing industry challenges.Articolo di analisi • Oct 04
Why Investors Shouldn't Be Surprised By Repligen Corporation's (NASDAQ:RGEN) 28% Share Price Surge
Repligen Corporation ( NASDAQ:RGEN ) shares have had a really impressive month, gaining 28% after a shaky period...Articolo di analisi • Sep 01
Is Repligen (NASDAQ:RGEN) A Risky Investment?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Articolo di analisi • Jul 29
Why Investors Shouldn't Be Surprised By Repligen Corporation's (NASDAQ:RGEN) P/S
When you see that almost half of the companies in the Life Sciences industry in the United States have price-to-sales...Nuova narrazione • May 26
Biomanufacturing Expansion Will Create New Global Opportunities
Strong demand in biomanufacturing and effective market expansion are driving sustained revenue growth and improved margins for Repligen.Seeking Alpha • Mar 20
Repligen: Ongoing Bioprocessing Market Recovery
Summary I reiterate a 'buy' rating for Repligen with a one-year price target of $175 per share, driven by strong bioprocessing market recovery. Repligen reported 3% organic revenue growth and 13% growth in non-COVID business, with record-high order intakes since Q2 FY22. The acquisition of 908 Devices' bioprocessing analytics portfolio enhances Repligen's process analytical technology, adding significant value to its offerings. Despite challenges in the protein business, I expect 12% organic revenue growth in FY25, supported by new product launches and market normalization. Read the full article on Seeking AlphaSeeking Alpha • Nov 12
Repligen Corporation's Earnings Preview: Expensive With Mixed Growth Prospects
Summary Repligen Corporation is a bioprocessing technology company focusing on process intensification, purification, and fluid management, with strategic acquisitions to enhance its capabilities. Though integration risks remain, RGEN's recent acquisition of Tantti Laboratory aims to bolster its chromatography and biomolecule purification capacities. The potential acquisition of Maravai LifeSciences could impact RGEN's future growth, but past failed attempts and divestment plans add uncertainty. Also, I believe international revenue exposure and foreign exchange volatility present additional risks for RGEN’s near-term financial performance. Despite a healthy underlying business, RGEN faces valuation concerns, tax loss harvesting, and uncertain growth, leading to a "Hold" rating ahead of its earnings report. Read the full article on Seeking AlphaSeeking Alpha • Jul 13
Repligen: Strong Filtration Growth, Offset By Other Challenges
Summary Repligen's Q1 revenue declined by 20% organically, driven by Covid-related business decline and reduced demand in China and protein business. Strong growth and pipelines in the core filtration business, with non-Covid filtration revenue surging by more than 15% in Q1. FY24 outlook includes -1% to +4% base revenue growth, with expectations of industry recovery in the second half of 2024 and a one-year price target of $150 per share. Read the full article on Seeking AlphaSeeking Alpha • May 30
Repligen Stock: Still Quite Overvalued
Summary Repligen Corporation stock has dropped 15% since our initial analysis of the stock just over six months ago. The company has posted a couple of quarterly earnings reports since then, and the company's balance sheet is in solid shape. That said, Repligen has hit a growth hiccup, and company insiders have picked up selling shares recently. An updated analysis around Repligen follows in the paragraphs below. Read the full article on Seeking AlphaAnalisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Utili della società |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | US$51m |
| Dec 31 2025 | US$6m | US$860k | US$49m |
| Sep 30 2025 | n/a | n/a | US$2m |
| Jun 30 2025 | n/a | n/a | -US$14m |
| Mar 31 2025 | n/a | n/a | -US$23m |
| Dec 31 2024 | US$7m | US$650k | -US$26m |
| Sep 30 2024 | n/a | n/a | -US$8m |
| Jun 30 2024 | n/a | n/a | US$9m |
| Mar 31 2024 | n/a | n/a | US$24m |
| Dec 31 2023 | US$5m | US$138k | US$36m |
Compensazione vs Mercato: La retribuzione totale di Olivier ($USD 6.11M ) è circa la media per le aziende di dimensioni simili nel mercato US ($USD 8.37M ).
Compensazione vs guadagni: La retribuzione di Olivier è stata coerente con le performance aziendali dell'ultimo anno.
AMMINISTRATORE DELEGATO
Olivier Loeillot (56 yo)
2.7yrs
Mandato
US$6,114,771
Compensazione
Mr. Olivier Loeillot is President of Repligen Corporation from October 02, 2023 & served as it's Chief Commercial Officer and serves as it's CEO & Director since September 1, 2024. Mr. Loeillot served a co...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| President | 2.7yrs | US$6.11m | Nessun dato | |
| CFO & Chief Compliance Officer | 2.8yrs | US$2.99m | 0.0069% $ 515.3k | |
| Chief Operating Officer | 6.3yrs | US$2.93m | 0.019% $ 1.4m | |
| Advisor | less than a year | US$671.00k | 0.15% $ 10.9m | |
| Senior Vice President of Research & Development | 9.7yrs | US$2.33m | 0.018% $ 1.4m | |
| Senior VP & Chief Product Officer | 2.1yrs | US$1.73m | 0.0029% $ 212.2k | |
| Chief Accounting Officer | less than a year | Nessun dato | Nessun dato | |
| Vice President of Investor Relations | 1.2yrs | Nessun dato | Nessun dato | |
| Senior VP & General Counsel | 1.4yrs | Nessun dato | Nessun dato | |
| Senior Vice President of Sales | 3.7yrs | Nessun dato | Nessun dato | |
| Senior Director of Marketing | 2.4yrs | Nessun dato | Nessun dato | |
| Global Head of Human Resources & VP | 3.4yrs | Nessun dato | Nessun dato |
2.5yrs
Durata media
56yo
Età media
Gestione esperta: Il team dirigenziale di RGEN è considerato esperto (durata media dell'incarico 2.5 anni).
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| President | 1.8yrs | US$6.11m | Nessun dato | |
| Independent Director | 10.7yrs | US$340.28k | 0.069% $ 5.2m | |
| Member of Scientific Advisory Board | 10.3yrs | Nessun dato | Nessun dato | |
| Independent Chair of the Board | 3.3yrs | US$316.28k | 0.013% $ 976.3k | |
| Lead Independent Director | 20.8yrs | US$355.28k | 0.16% $ 12.1m | |
| Independent Director | 2.3yrs | US$318.80k | 0.0036% $ 265.9k | |
| Member of Scientific Advisory Board | 10.3yrs | Nessun dato | Nessun dato | |
| Member of Scientific Advisory Board & Independent Director | 10.3yrs | US$300.28k | 0.0051% $ 382.0k | |
| Member of Scientific Advisory Board | 10.3yrs | Nessun dato | Nessun dato | |
| Independent Director | 6.3yrs | US$305.28k | 0.0071% $ 530.2k | |
| Member of Scientific Advisory Board | no data | Nessun dato | Nessun dato | |
| Independent Director | 12yrs | US$311.75k | 0.0079% $ 586.1k |
10.3yrs
Durata media
66yo
Età media
Consiglio di amministrazione esperto: Il consiglio di amministrazione di RGEN è composto da personale esperto e esperto (durata media dell'incarico 10.3 anni).
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/06/22 16:52 |
| Prezzo dell'azione a fine giornata | 2026/06/18 00:00 |
| Utili | 2026/03/31 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; disponiamo inoltre di guide su come utilizzare i nostri report e di tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Repligen Corporation è coperta da 30 analisti. 21 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Luke Sergott | Barclays |
| Robert Wasserman | Benchmark Company |
| Hugo Solvet | BNP Paribas |